 |
102 Diseases |  |
11 Trials |
|
11 Trials |  |
751 News |  |
| «123456789 |
- fluvastatin / Generic mfg., celecoxib oral / Generic mfg.
Enrollment open: FLUVABREX: Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas (clinicaltrials.gov) - Jul 23, 2014
P1, N=35, Recruiting, Sponsor: Centre Oscar Lambret
Not yet recruiting --> Recruiting
- |||| frovocimab (LY3015014) / Eli Lilly
Trial completion: A Study of LY3015014 in Participants With High Cholesterol (clinicaltrials.gov) - Jul 1, 2014
P2, N=528, Completed, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- fluvastatin / Generic mfg., celecoxib oral / Generic mfg.
New P1 trial: FLUVABREX: Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas (clinicaltrials.gov) - Apr 13, 2014
P1, N=35, Not yet recruiting, Sponsor: Centre Oscar Lambret
- fluvastatin / Generic mfg.
Enrollment open: Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer (clinicaltrials.gov) - Feb 18, 2014
P2, N=40, Recruiting, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| frovocimab (LY3015014) / Eli Lilly
Enrollment closed: A Study of LY3015014 in Participants With High Cholesterol (clinicaltrials.gov) - Feb 4, 2014
P2, N=528, Active, not recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- fluvastatin / Generic mfg.
New P2 trial: Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer (clinicaltrials.gov) - Nov 21, 2013
P2, N=40, Recruiting, Sponsor: University Health Network, Toronto
- Trial initiation date: ESH-CHL-SHOT: Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives (clinicaltrials.gov) - Oct 28, 2013
P4, N=7500, Recruiting, Sponsor: Istituto Auxologico Italiano
Recruiting --> Active, not recruiting Initiation date: Sep 2012 --> Apr 2013
- Enrollment open: ESH-CHL-SHOT: Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives (clinicaltrials.gov) - Oct 28, 2013
P4, N=7500, Recruiting, Sponsor: Istituto Auxologico Italiano
Initiation date: Sep 2012 --> Apr 2013 Not yet recruiting --> Recruiting
- simvastatin / Generic mfg., ribavirin / Generic mfg., fluvastatin / Generic mfg.
Trial termination: HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity (clinicaltrials.gov) - Aug 20, 2013
P1, N=20, Terminated, Sponsor: Bader, Ted, M.D.
Not yet recruiting --> Recruiting Recruiting --> Terminated; Principal Investigator retiring
- ||| fluvastatin / Generic mfg.
Enrollment change: Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (clinicaltrials.gov) - Jul 21, 2013
P4, N=242, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Terminated; Principal Investigator retiring N=440 --> 242
- |||| fluvastatin / Generic mfg.
Trial completion: Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (clinicaltrials.gov) - Jul 21, 2013
P4, N=242, Completed, Sponsor: Novartis Pharmaceuticals
N=440 --> 242 Recruiting --> Completed
- ||||| frovocimab (LY3015014) / Eli Lilly
New P2 trial: A Study of LY3015014 in Participants With High Cholesterol (clinicaltrials.gov) - Jun 30, 2013
P2, N=528, Active, not recruiting, Sponsor: Eli Lilly and Company
- fluvastatin / Generic mfg.
Trial withdrawal: A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C (clinicaltrials.gov) - Jun 27, 2013
P2, N=0, Withdrawn, Sponsor: University of Chicago
Recruiting --> Completed Terminated --> Withdrawn
- Enrollment change: ISCAP: Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI (clinicaltrials.gov) - Apr 27, 2013
P4, N=2884, Completed, Sponsor: Peking University First Hospital
Terminated --> Withdrawn N=2160 --> 2884
- Trial completion: ISCAP: Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI (clinicaltrials.gov) - Apr 27, 2013
P4, N=2884, Completed, Sponsor: Peking University First Hospital
N=2160 --> 2884 Recruiting --> Completed
- fluvastatin / Generic mfg.
Biomarker, Enrollment change, IO biomarker, Surgery: Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer (clinicaltrials.gov) - Dec 11, 2012
P2, N=35, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed N=60 --> 35
- fluvastatin / Generic mfg.
Biomarker, Trial completion, IO biomarker, Surgery: Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer (clinicaltrials.gov) - Dec 11, 2012
P2, N=35, Completed, Sponsor: University of California, San Francisco
N=60 --> 35 Recruiting --> Completed
- | New P4 trial: StaRT-CABG: Statin Recapture Therapy Before Coronary Artery Bypass Grafting (clinicaltrials.gov) - Oct 25, 2012
P4, N=2630, Recruiting, Sponsor: University of Cologne
- everolimus / Generic mfg., fluvastatin / Generic mfg., rosuvastatin / Generic mfg.
Trial completion: The Rosuvastatin In TrAnsplant Recipients Study (clinicaltrials.gov) - Oct 10, 2012
P4, N=20, Completed, Sponsor: University of Oslo School of Pharmacy
Recruiting --> Completed Recruiting --> Completed
- ||||| fluvastatin XL / Generic mfg., fluvastatin / Generic mfg.
New P4 trial: FAITH: Fluvastatin AmelIorates aTHerosclerosis Study (clinicaltrials.gov) - Sep 5, 2012
P4, N=140, Recruiting, Sponsor: Beijing Anzhen Hospital
- simvastatin / Generic mfg., ribavirin / Generic mfg., fluvastatin / Generic mfg.
Trial initiation date: HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity (clinicaltrials.gov) - Aug 19, 2012
P1, N=20, Terminated, Sponsor: Bader, Ted, M.D.
Recruiting --> Completed Initiation date: Aug 2011 --> Mar 2012
- fluvastatin / Generic mfg., rosuvastatin / Generic mfg.
Enrollment change: Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin (clinicaltrials.gov) - Aug 12, 2012
P2, N=40, Completed, Sponsor: Bader, Ted, M.D.
Initiation date: Aug 2011 --> Mar 2012 N=170 --> 40
- fluvastatin / Generic mfg., rosuvastatin / Generic mfg.
Trial completion: Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin (clinicaltrials.gov) - Aug 12, 2012
P2, N=40, Completed, Sponsor: Bader, Ted, M.D.
N=170 --> 40 Recruiting --> Completed
- fluvastatin / Generic mfg.
Trial completion, Preclinical: Fluvastatin Versus Hepatitis C Virus (clinicaltrials.gov) - Jul 25, 2012
P=N/A, N=32, Completed, Sponsor: Bader, Ted, M.D.
Recruiting --> Completed Active, not recruiting --> Completed
- | New P4 trial: ESH-CHL-SHOT: Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives (clinicaltrials.gov) - Mar 25, 2012
P4, N=7500, Recruiting, Sponsor: Istituto Auxologico Italiano
- ||||| fluvastatin / Generic mfg.
New P4 trial: Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (clinicaltrials.gov) - Mar 8, 2012
P4, N=242, Completed, Sponsor: Novartis Pharmaceuticals
- everolimus / Generic mfg., fluvastatin / Generic mfg., rosuvastatin / Generic mfg.
New P4 trial: The Rosuvastatin In TrAnsplant Recipients Study (clinicaltrials.gov) - Jan 31, 2012
P4, N=20, Completed, Sponsor: University of Oslo School of Pharmacy
- New P4 trial, HEOR, Cost effectiveness: Randomized controlled clinical trial phase IV to validate a cost-effective tool to optimize statin treatment of diabetic dyslipidemia in primary care (EUDRACT) - Nov 9, 2011
P4, N=28, Ongoing, Sponsor: Eduardo García Díaz
- ||| valsartan / Generic mfg., fluvastatin / Generic mfg.
Enrollment change: Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction (clinicaltrials.gov) - Nov 6, 2011
P4, N=213, Completed, Sponsor: Novartis
Active, not recruiting --> Completed N=100 --> 213